IP Library Granted Patent US 7,329,423
Granted Patent B2
US 7,329,423 · App. 10/482,797 · Granted Feb 12, 2008

Compositions comprising thylakoids useful in the modulation of inflammation process

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,329,423
App. No.
10/482,797
Granted
Feb 12, 2008
Kind
B2
Abstract

A thylakoid extract that is preferably stabilized and activable for treating inflammation is described. Different types of cell or tissue targets and inflammatory stimuli have been used to evaluate the performance of the extract, which, in all cases successfully modulate inflammation through a balance of pro/anti-inflammatory cytokines. Compositions comprising the extract and other anti-inflammatory agents, such as glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) are further disclosed and claimed.

Claims (22)

1. A method for modulating an inflammatory process in a subject, said method comnrising administering an effective amount of a thylakoid extract and an an effective amount an anti-inflammation agent to said subiect to modulate the inflammatory process.

2. The method of claim 1 , comprising modulating an amount of (a) pro-inflammatory cytokines, (b) anti-inflammatory cytokines or (c) both (a) and (b) induced during the inflammatory process.

3. The methoduse of claim 2 , wherein said pro-inflammatory cytokines comprise tumor necrosis factor-alpha (TNF-α).

4. The method of claim 2 , wherein said anti-inflammatory cytokines comprise interleukin-10.

5. The method of claim 2 , wherein the amount of anti-inflammatory cytokines is increased.

6. The method of claim 1 , wherein said anti-inflammatory agent is a glucocorticoid.

7. The method of claim 1 , wherein said anti-inflammatory agent is a non-steroidal anti-inflammatory drug (NSAID).

8. The method of claim 1 , wherein the extract is administered at a dose of about 0.00005 to 500 mg per kg of a subject's body weight.

9. The method of claim 1 , wherein the extract is administered at a dose of about 0.05 to 5 mg per kg of a subject's body weight.

10. The method of claim 1 , wherein the administration is topical.

11. The method of claim 10 , wherein said administration comprises about 0.1 μg to 1 mg of extract per cm 2 of surface of a subject's skin or mucosae.

12. The method of claim 10 , wherein said administration comprises about 1 μg to 200 μg of extract per cm 2 of surface of a subject's skin or mucosae.

13. A composition to inhibit inflammation in a subject, comprising an effective amount of an anti-inflammatory agent and an effective amount of a thylakoid extract.

14. The composition of claim 13 , wherein said anti-inflammatory agent is a glucocorticoid.

15. The composition of claim 13 , wherein said anti-inflammatory agent is a non-steroidal anti-inflammatory drug (NSAID).

16. The composition of claim 13 , which is topical.

17. The composition of claim 16 , wherein said effective amount of extract is about 0.1 μg to 1 mg per cm 2 of surface of a subject's skin or mucosae.

18. The composition of claim 16 , wherein said effective amount of extract is about 1 μg to 200 μg per cm 2 of a subject's surface of skin or mucosae.

19. The composition of claim 13 , wherein said effective amount of extract is about 0.00005 to 500 mg per Kg of a subject's body weight.

20. The composition of claim 13 , wherein said effective amount of extract is about 0.05 to 5 mg per Kg of a subject's body weight.

21. The composition of claim 13 , wherein said thylakoid extract comprises functional photosynthetic pigments.

22. The composition of claim 16 , wherein said effective amount of extract is about 0.00005 to 5%.

Assignments (9)
CORRECTIVE ASSIGNMENT TO CORRECT THE REVERSING ASSIGNOR AND ASSIGNEE INFORMATION PREVIOUSLY RECORDED AT REEL: 49895 FRAME: 301. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 30, 2021
From: INVESTISSEMENT QUÉBEC
To: GROUPE SANTÉ DEVONIAN INC.
Reel/Frame 057688/0869 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 16154364 PREVIOUSLY RECORDED AT REEL: 048359 FRAME: 0174. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Jun 28, 2021
From: DEVONIAN HEALTH GROUP INC.
To: GRX HEALTHCARE INC.
Reel/Frame 057292/0433 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2019
From: GROUPE SANTÉ DEVONIAN INC.
To: INVESTISSEMENT QUÉBEC
Reel/Frame 049895/0301 →
SECURITY INTEREST Recorded Feb 18, 2019
From: DEVONIAN HEALTH GROUP INC.
To: GRX HEALTHCARE INC.
Reel/Frame 048359/0174 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 035752 FRAME 0878. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Jul 30, 2015
From: PURGENESIS TECHNOLOGIES INC.
To: GROUPE SANTÉ DEVONIAN
Reel/Frame 036233/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2015
From: PURGENESIS TECHNOLOGIES INC.
To: GROUPE SANTÉ DEVONION
Reel/Frame 035752/0878 →
CHANGE OF NAME Recorded May 27, 2015
From: PURECELL TECHNOLOGIES INC.
To: PURGENESIS TECHNOLOGIES INC.
Reel/Frame 035784/0191 →
SECURITY INTEREST Recorded Jul 9, 2014
From: PURGENESIS TECHNOLOGIES INC.
To: INVESTISSEMENT QUÉBEC
Reel/Frame 033283/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2004
From: ANDERSEN, ALAIN; BISSONNETTE, ELYSE; DROUIN, REJEAN; PURCELL, MARC
To: PURECELL TECHNOLOGIES INC.
Reel/Frame 015978/0426 →